NASDAQ:ATRCAtriCure Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AtriCure Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $31.78 -1.21 (-3.67 %) (As of 04/6/2020 08:43 AM ET) Add Compare Share Today's Range$30.66Now: $31.78▼$33.3850-Day Range$24.49MA: $35.20▼$43.8452-Week Range$22.57Now: $31.78▼$44.51Volume439,005 shsAverage Volume469,830 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/ABeta0.55 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.00, AtriCure has a potential upside of 38.5% from its current price of $31.78.Amount of Analyst CoverageAtriCure has only been the subject of 4 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesAtriCure has received 466 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAtriCure has received 348 “underperform” votes. (Add your “underperform” vote.)Community SentimentAtriCure has received 57.25% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote “Outperform” if you believe ATRC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,743,628.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions87.30% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to decrease by -24.58% in the coming year, from ($1.18) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -34.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -34.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 5.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.47 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ATRC Previous Symbol CUSIP04963C20 CIK1323885 Webhttp://www.atricure.com/ Phone513-755-4100Debt Debt-to-Equity Ratio0.30 Current Ratio2.87 Quick Ratio2.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$230.81 million Price / Sales5.51 Cash FlowN/A Price / Cash FlowN/A Book Value$6.25 per share Price / Book5.08Profitability EPS (Most Recent Fiscal Year)($1.07) Net Income$-35,190,000.00 Net Margins-15.25% Return on Equity-16.26% Return on Assets-8.91%Miscellaneous Employees620 Outstanding Shares40,050,000Market Cap$1.27 billion Next Earnings Date4/23/2020 (Estimated) OptionableOptionable Receive ATRC News and Ratings via Email Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ATRC Rates by TradingView AtriCure (NASDAQ:ATRC) Frequently Asked Questions How has AtriCure's stock been impacted by COVID-19 (Coronavirus)? AtriCure's stock was trading at $35.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATRC shares have decreased by 9.9% and is now trading at $31.78. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of AtriCure? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AtriCure. When is AtriCure's next earnings date? AtriCure is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for AtriCure. How were AtriCure's earnings last quarter? AtriCure Inc. (NASDAQ:ATRC) issued its quarterly earnings results on Tuesday, February, 18th. The medical device company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.01. The medical device company earned $44.77 million during the quarter, compared to the consensus estimate of $60.60 million. AtriCure had a negative return on equity of 16.26% and a negative net margin of 15.25%. AtriCure's quarterly revenue was down 15.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. View AtriCure's earnings history. What guidance has AtriCure issued on next quarter's earnings? AtriCure issued an update on its FY20 earnings guidance on Tuesday, February, 18th. The company provided EPS guidance of -$1.24 to -$1.14 for the period, compared to the Thomson Reuters consensus EPS estimate of ($1.09). The company issued revenue guidance of $254 million to $261 million, compared to the consensus revenue estimate of $258.63 million. What price target have analysts set for ATRC? 7 equities research analysts have issued 1 year target prices for AtriCure's shares. Their forecasts range from $30.00 to $52.00. On average, they expect AtriCure's share price to reach $44.00 in the next year. This suggests a possible upside of 38.5% from the stock's current price. View analysts' price targets for AtriCure. Has AtriCure been receiving favorable news coverage? Press coverage about ATRC stock has been trending very negative on Monday, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AtriCure earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAtriCure. Who are some of AtriCure's key competitors? Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD) and Masimo (MASI). What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Allergan (AGN), Enterprise Products Partners (EPD), Neurocrine Biosciences (NBIX), Walt Disney (DIS), BioTelemetry (BEAT), bluebird bio (BLUE) and Cellectis (CLLS). Who are AtriCure's key executives? AtriCure's management team includes the following people: Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)Mr. Douglas J. Seith, Chief Operating Officer (Age 53)Mr. Salvatore Privitera, Chief Technology Officer (Age 52)Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41) What is AtriCure's stock symbol? AtriCure trades on the NASDAQ under the ticker symbol "ATRC." How do I buy shares of AtriCure? Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AtriCure's stock price today? One share of ATRC stock can currently be purchased for approximately $31.78. How big of a company is AtriCure? AtriCure has a market capitalization of $1.27 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 620 workers across the globe. View additional information about AtriCure. What is AtriCure's official website? The official website for AtriCure is http://www.atricure.com/. How can I contact AtriCure? AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100. This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: What is a price target?
